- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Penn Files a Second Suit Against Noted Cancer Researcher
23 February 2012 6:01 pm
Craig Thompson, president of the Memorial Sloan-Kettering Cancer Center in New York City, yesterday was hit with a second lawsuit alleging that he made an improper business deal to exploit his research on the metabolism of cancer cells.
The University of Pennsylvania filed a complaint in U.S. federal court in Manhattan charging that Thompson—a former Penn employee—failed to share intellectual property from his discoveries with the university as he was required to do. Instead, Penn claims, Thompson published his group's findings of variant cancer cell enzymes in Nature and Cancer Cell while helping a private company seek patents on the discoveries. This repeats some charges of a complaint filed in December, when Thompson was sued by the Leonard and Madlyn Abramson Family Cancer Research Institute—part of a university linked operation that Thompson formerly directed. It accused him of improperly sharing intellectual property with a company he helped launch, Agios Pharmaceuticals of Cambridge, Massachusetts. Penn and the Abramson center have both included Agios as a defendant.
In its complaint, Penn alleges that Thompson violated the university's patent rules and "breached his fiduciary duty to the university" by "failing to disclose to the university research and discoveries." Instead, it claims, he shared the findings with Agios, which filed for patents, and disclosed his work in international journals, "to the detriment of the university."
Agios, with $150 million in outside backing, hopes to develop new therapies based on this research.
In response, Thompson said, "I believe the allegations of Penn's complaint to be without merit, both factually and legally. I am very disappointed that Penn chose to file its lawsuit without making any effort to speak with me or ascertain the true facts before filing a suit that unjustly harms my reputation." An Agios spokesperson said that Agios "believes it has done nothing wrong … and fully expects to be vindicated."